Cellectar Biosciences (CLRB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Cellectar Biosciences (CLRB) is Moderate Underperform.

The composite score behind that read is -0.30, weighing +0.00 of bullish evidence against -0.44 bearish.

Cellectar Biosciences last closed at $1.45, +3.57% on the session.

Against the IVW growth benchmark the position is +2.77% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for CLRB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cellectar Biosciences in the 6th percentile on return on equity, where 100 is best.

Cellectar Biosciences is classified under Health Care / Biotechnology, with a market capitalisation of $13.23M.

StockMap tracks Cellectar Biosciences as the 347th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Cellectar Biosciences ranks 364th of 381 in the group, against a group median of -0.08.